We develop Pentarins™, which are novel miniaturized drug conjugates uniquely designed to target, penetrate and eradicate solid tumors.
Developing novel cancer therapies that address the challenges of effectively treating patients with solid tumors.
Tarveda creates Pentarins, targeted miniaturized drug conjugates that remain miniature by design to overcome the challenges that limit the efficacy of larger therapies such as antibody drug conjugates that are in use and development today. Specifically, our Pentarins are designed to effectively penetrate into solid tumors, target cancer cells selectively, drive sufficient accumulation of the drug at the site of the tumor, release effective, potent payloads into the targeted cancer cells, and cause cancer cell death within solid tumors.
Tarveda’s innovative cancer therapies are based on the company’s Pentarin platform, through which we create our novel, miniaturized drug conjugates. With our platform capabilities and cancer research and development expertise, our team creates Pentarins comprised of an innovative targeting ligand, joined through an optimized linker to a potent payload, that are designed to effectively penetrate into solid tumors to cause cancer cell death.
Pentarins are engineered to possess tuned pharmacokinetic and biodistribution properties for anti-cancer efficacy, through inherent design of the conjugate or by the incorporation of other technologies that enhance the profile of the conjugate. The result is a product platform enabling the development of novel Pentarins that therapeutically drive efficacy without making the therapeutic too large to penetrate into solid tumors.
Advancing our proprietary Pentarin pipeline
Through our Pentarin platform, Tarveda is developing an internal pipeline of proprietary miniaturized drug conjugates with tuned properties to improve solid tumor treatment. We are advancing Pentarins directed against cell surface and intracellular tumor targets as we focus on treating cancers where there is a significant unmet need. Tarveda is developing its pipeline of Pentarins to address a wide range of solid cancers. Our pipeline includes PEN-221, a novel cancer therapeutic that is highly selective for the somatostatin receptor that is in a Phase 1/2a clinical trial. PEN-221 is being developed to treat neuroendocrine cancers including small cell lung cancer. PEN-866 is highly selective for Heat Shock Protein 90 (HSP90) and has demonstrated enduring tumor regressions in xenograft models of small-cell lung cancer, pancreatic cancer, ovarian cancer and Ewing’s sarcoma. To see our pipeline of Pentarins, [click here].
Our proprietary platform is applicable to a range of solid tumor targets, and we are extending our broad internal pipeline of candidates to address multiple areas of unmet need. Now with our growing pipeline of Pentarins, our platform can serve as the foundation for developing efficacious Pentarins by leveraging and incorporating proprietary targeting moieties and/or payloads of pharmaceutical companies and other collaborators.
To inquire about Pentarin collaborations, contact us at email@example.com